The disclosure provides methylome analysis using DNA methylation biomarkers for predicting ovarian cancer prognosis and detecting malignant ovarian cancer. Being independent prognostic factors for patients with current treatment protocols, these DNA methylations are also important biomarkers for treating patients with individualized medicine in future including using chemotherapy, especially the demethylation agents or other epigenetic drugs.
|Original language||Chinese (Traditional)|
|Journal||US Patent App|
|Publication status||Published - Mar 7 2013|